GT200100113AA - Nuevo procedimiento para la preparacion de pirazolopirimidinonas . - Google Patents

Nuevo procedimiento para la preparacion de pirazolopirimidinonas .

Info

Publication number
GT200100113AA
GT200100113AA GT200100113AK GT200100113K GT200100113AA GT 200100113A A GT200100113A A GT 200100113AA GT 200100113A K GT200100113A K GT 200100113AK GT 200100113 K GT200100113 K GT 200100113K GT 200100113A A GT200100113A A GT 200100113AA
Authority
GT
Guatemala
Prior art keywords
new procedure
pirazolopirimidinonas
preparation
alquilpiperazinil
pirimidin
Prior art date
Application number
GT200100113AK
Other languages
English (en)
Inventor
Mark Edward Bunnage
Philip Charles Levett
Nicholas Murray Thomson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200100113A(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0015462A external-priority patent/GB0015462D0/en
Priority claimed from GB0105878A external-priority patent/GB0105878D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of GT200100113AA publication Critical patent/GT200100113AA/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN NUEVO PROCEDIMIENTO PARA LA PRODUCCIÓN DE DERIVADOS DE 4-ALQUILPIPERAZINIL-SULFONILFENIL- Y 4-ALQUILPIPERAZINIL-SULFONIL-PIRIDINIL-DIHIDROPIRAZOLO[4,3D]PIRIMIDIN-7-ONA Y EN PARTICULAR EL FARMACO ANTIIMPOTENCIA SILDENAFILO Y SUS ANÁLOGOS. EL SIDENAFILO (5-[2-ETOXI-5-(4-METILPIPERAZIN-1-ILSULFONIL)FENIL]-1-METIL-3-N-PROPIL-1,6-DIHIDRO-7H-PIRAZOLO[4,3-D]PIRIMIDIN-7-ONA) QUE ES EL INGREDIENTE ACTIVO EN EL VIAGRA.
GT200100113AK 2000-06-22 2001-06-14 Nuevo procedimiento para la preparacion de pirazolopirimidinonas . GT200100113AA (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015462A GB0015462D0 (en) 2000-06-22 2000-06-22 Novel process for the preparation of pyrazolopyrimidinones
GB0105878A GB0105878D0 (en) 2001-03-09 2001-03-09 Novel process for the preparation of pyrazoloprimidinones

Publications (1)

Publication Number Publication Date
GT200100113AA true GT200100113AA (es) 2006-04-10

Family

ID=26244537

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200100113AK GT200100113AA (es) 2000-06-22 2001-06-14 Nuevo procedimiento para la preparacion de pirazolopirimidinonas .
GT200100113A GT200100113A (es) 2000-06-22 2001-06-14 Nuevo procedimiento para la preparacion de pirazolopirimidinonas

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT200100113A GT200100113A (es) 2000-06-22 2001-06-14 Nuevo procedimiento para la preparacion de pirazolopirimidinonas

Country Status (26)

Country Link
EP (1) EP1296983B1 (es)
JP (1) JP2004501154A (es)
KR (1) KR100525699B1 (es)
AP (1) AP2001002195A0 (es)
AR (1) AR028729A1 (es)
AT (1) ATE282619T1 (es)
AU (2) AU6259201A (es)
BR (1) BR0111864A (es)
CA (1) CA2411957C (es)
CZ (1) CZ20024130A3 (es)
DE (1) DE60107248T2 (es)
ES (1) ES2231498T3 (es)
GT (2) GT200100113AA (es)
HK (1) HK1079198A1 (es)
HU (1) HUP0301207A3 (es)
IL (1) IL152983A0 (es)
MX (1) MXPA02012887A (es)
MY (1) MY127737A (es)
PA (1) PA8520001A1 (es)
PE (1) PE20020091A1 (es)
PL (1) PL360299A1 (es)
PT (1) PT1296983E (es)
SV (1) SV2002000502A (es)
TN (1) TNSN01092A1 (es)
WO (1) WO2001098303A1 (es)
YU (1) YU84702A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE69911448T2 (de) * 1998-10-23 2004-04-08 Pfizer Inc. Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen

Also Published As

Publication number Publication date
JP2004501154A (ja) 2004-01-15
KR100525699B1 (ko) 2005-11-03
GT200100113A (es) 2002-06-04
YU84702A (sh) 2005-09-19
TNSN01092A1 (fr) 2005-11-10
AU6259201A (en) 2002-01-02
PA8520001A1 (es) 2003-09-05
CA2411957A1 (en) 2001-12-27
KR20030017556A (ko) 2003-03-03
IL152983A0 (en) 2003-06-24
DE60107248T2 (de) 2005-12-01
CA2411957C (en) 2007-09-18
DE60107248D1 (de) 2004-12-23
PL360299A1 (en) 2004-09-06
ATE282619T1 (de) 2004-12-15
PT1296983E (pt) 2005-02-28
SV2002000502A (es) 2002-07-03
EP1296983A1 (en) 2003-04-02
PE20020091A1 (es) 2002-02-21
ES2231498T3 (es) 2005-05-16
CZ20024130A3 (cs) 2004-01-14
MY127737A (en) 2006-12-29
EP1296983B1 (en) 2004-11-17
AP2001002195A0 (en) 2002-12-21
HK1079198A1 (en) 2006-03-31
MXPA02012887A (es) 2003-05-14
AU2001262592B2 (en) 2006-07-06
WO2001098303A1 (en) 2001-12-27
BR0111864A (pt) 2003-07-01
HUP0301207A3 (en) 2006-02-28
HUP0301207A2 (hu) 2003-08-28
AR028729A1 (es) 2003-05-21

Similar Documents

Publication Publication Date Title
DZ3384A1 (fr) Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
DK1720551T3 (da) Alkaloidformuleringer
MA26881A1 (fr) 5-alkyl-pyrido [2,3-d]pyrimidines inhibitrices de tyrosine-kinases.
WO2004064769A3 (en) Methods for making and using topical delivery agents
SV2002000205A (es) Compuestos farmaceuticos ref. x-01095
AU7102201A (en) Propane-1,3-dione derivatives
DK1296661T3 (da) Fremgangsmåde til fremstilling af hurtigt henfaldende administrerbare former til frisætning af aktive indgredienser i det orale hulrum eller i legemshulrum
DE60129849D1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
BRPI0412029A (pt) formulações para microprojeções revestidas contendo contra-ìons não-voláteis
HN2001000190A (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
HN2000000204A (es) Derivados de la purina
HN2000000166A (es) Composicion de ovulos intravaginales de clindamicina
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
EP1750680A4 (en) FORMULATIONS OF WATER-SOLUBLE AGENTS COATED WITH SLOW RELEASE COMPRESSION
GT200100113AA (es) Nuevo procedimiento para la preparacion de pirazolopirimidinonas .
GT200200015A (es) Formulacion agroquimica
EP1250937A3 (en) Controlled dissolution of active ingredients
HN2002000050A (es) Compuestos farmaceuticamente activos
AR030378A1 (es) Empleo de triazintrion-sulfonas para la lucha contra la coccidiosis
DK1847258T3 (da) Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thie-no[3,2-c]pyridin-derivater
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
SE0202365D0 (sv) New formulation and use thereof
SV2001000570A (es) Agente terapeutico cristalino ref. pcs22011afae/bb